Alzamend Neuro Inc (ALZN)
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative and psychiatric disorders. Its pipeline includes AL001, a therapeutic combination of lithium, proline, and salicylate being developed for conditions such as Alzheimer’s disease, bipolar disorder, post-traumatic stress disorder, major depressive disorder, and other related disorders. The company is also advancing ALZN002, a cell-based therapeutic vaccine designed to help restore the immune system’s ability to combat Alzheimer’s disease. Incorporated in 2016, Alzamend Neuro is headquartered in Atlanta, Georgia. Its common stock is listed on the NASDAQ exchange under the ticker ALZN.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ALZN
|
$1.71
|
29.8% Upside
|
Undervalued
|
$25 1,793.9% Upside
|
—
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
September 15, 2026
|
-0.7x
|
2.3x
|
—
|
4.794 M
|
2.408 M
|
0.0%
|
99.7%
|
-26.0
|
—
|
81.8%
|
